Johan Lennerstrand
Docent i experimentell virologi vid Institutionen för medicinska vetenskaper; Klinisk Mikrobiologi
- Telefon:
- 018-611 02 65
- Mobiltelefon:
- 070-432 23 37
- E-post:
- Johan.Lennerstrand@medsci.uu.se
- Besöksadress:
- Dag Hammarskjölds väg 38
- Postadress:
- Klinisk Mikrobiologi, Hub
Dag Hammarskjölds väg 38
751 85 Uppsala
- Akademiska meriter:
- Docent
Mer information visas för dig som medarbetare om du loggar in.
Publikationer
Senaste publikationer
- Identification of novel and potent inhibitors of SARS-CoV-2 main protease from DNA-encoded chemical libraries (2024)
- From SARS-CoV-2 to Global Preparedness (2024)
- Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023 (2023)
- Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals (2022)
- Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses (2022)
Alla publikationer
Artiklar
- Identification of novel and potent inhibitors of SARS-CoV-2 main protease from DNA-encoded chemical libraries (2024)
- From SARS-CoV-2 to Global Preparedness (2024)
- Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023 (2023)
- Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals (2022)
- Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses (2022)
- SARS-CoV-2 variants of concern and spike protein mutational dynamics in a Swedish cohort during 2021, studied by Nanopore sequencing (2022)
- Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitors (2021)
- SHARED (2021)
- Global Prevalence of Adaptive and Prolonged Infections' Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein (2021)
- Identification of a C2-symmetric diol based human immunodeficiency virus protease inhibitor targeting Zika virus NS2B-NS3 protease (2020)
- Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro (2020)
- Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment (2019)
- A Real World Resistance Profile of Virologic Failures Collected from an International Collaboration (SHARED) (2018)
- Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016 (2018)
- The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1 (2018)
- Protein backbone flexibility pattern is evolutionarily conserved in the Flaviviridae family (2018)
- Comparative genome analysis of Alkhumra hemorrhagic fever virus with Kyasanur forest disease and tick-borne encephalitis viruses by the in silico approach (2018)
- Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals (2018)
- Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach. (2018)
- Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance (2017)
- Sequencing of Hepatitis C Virus for Detection of Resistance to Direct-Acting Antiviral Therapy (2017)
- Computational prediction of Usutu virus E protein B cell and T cell epitopes for potential vaccine development. (2017)
- Analysis of hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing (2016)
- SYBR Green II Dye-Based Real-Time Assay for Measuring Inhibitor Activity Against HIV-1 Reverse Transcriptase (2016)
- Hepatitis C Genotype 4R Resistance-Associated Polymorphisms (2016)
- Hepatitis C virus drug resistance-associated substitutions (2015)
- Transmission of hepatitis C virus among intravenous drug users in the Uppsala region of Sweden (2014)
- Implications of baseline polymorphisms for potential resistance to NS3 protease and NS5A inhibitors in hepatitis C virus genotypes 1a, 2b and 3a (2013)
- Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a (2013)
- Homogeneous assay for real-time and simultaneous detection of thymidine kinase 1 and deoxycytidine kinase activities (2013)
- Environmental Levels of the Antiviral Oseltamivir Induce Development of Resistance Mutation H274Y in Influenza A/H1N1 Virus in Mallards (2011)
- Detection of Resistance Mutations to Antivirals Oseltamivir and Zanamivir in Avian Influenza A Viruses Isolated from Wild Birds (2011)
- Selection and Characterization of HIV-1 with a Novel S68 Deletion in Reverse Transcriptase (2011)
- Nya antivirala läkemedel mot hepatit C i kliniska studier (2009)
- Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate (2007)
- Influence of naturally occurring insertions in the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and mutation frequencies in vitro (2006)
- Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation (2003)
- Use of HIV-1 reverse transcriptase recovered from human plasma for phenotypic drug susceptibility testing (2003)
- Application of a colorimetric chain-termination assay for characterization of reverse transcriptase from 3-azido-2,3-deoxythymidine-resistant HIV isolates (2002)
- Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants (2001)
- Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine (2001)
- The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer (2001)
- Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. (1998)
- Prognostic significance of TP53 accumulation in human primary breast cancer (1996)
- A Method for Combined Immunoaffinity Purification and Assay of HIV-1 Reverse Transcriptase Activity Useful for Crude Samples (1996)
- Prognostic significance of p53 overexpression in primary breast cancer (1995)
- HIV-1 reverse transcriptase inhibiting antibody titer in serum (1992)
- Carrier bound templates for single tube reverse transcriptase assays and for combined purification and activity analyses, with special reference to HIV (1991)
- HIV reverse transcriptase inhibiting antibodies detected by a new technique (1991)
- Oseltamivir- and Zanamivir-Resistance Related Mutations in Influenza A Viruses Isolated from Wild Mallards in Sweden Studied by a Colorimetric Neuraminidase Inhibition Assay
Böcker
Kapitel
Konferenser
